Switching from rituximab to eculizumab in patients with AQP4+NMOSD in the United States: Impact on hospitalisations and comorbidities

被引：0
|
作者：
Lee, Justin [1 ]
Kielhorn, Adrian [1 ]
Fam, Sami [1 ]
Riser, Emily [2 ]
Flanagan, Eoin [3 ]
机构：
[1] Alexion, AstraZeneca Rare Dis, Boston, MA USA
[2] Alabama Neurol Associates, Birmingham, AL USA
[3] Mayo Clin, Dept Neurol, Rochester, MN USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P358/1445
引用
收藏
页码：391 / 392
页数：2
相关论文
共 50 条
  • [41] BUDGET IMPACT ANALYSIS OF BIRCH TRITERPENES FOR PATIENTS WITH EPIDERMOLYSIS BULLOSA FROM A UNITED STATES PERSPECTIVE
    Stevenson, A.
    Tao, C.
    Pinsonault, T.
    Kenney, J. T.
    Brody, P.
    Collins, C.
    Dorling, P.
    Lee, Wine L.
    VALUE IN HEALTH, 2024, 27 (12) : S123 - S124
  • [42] Long-term safety, effectiveness, and corticosteroid sparing effects of eculizumab in patients with AQP4Ab+neuromyelitis optica spectrum disorder: realworld data from Japan
    Nakahara, Jin
    Nakashima, Ichiro
    Yokote, Hiroaki
    Isobe, Noriko
    Yajima, Toshitaka
    Hasegawa, Kou
    Fujihara, Kazuo
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 143 - 144
  • [43] Clinical Outcomes of 200 Multiple Sclerosis Patients Switching from Natalizumab to Alemtuzumab in a Single United States MS Center
    LaGanke, Christopher
    Adcock, Amanda
    NEUROLOGY, 2016, 86
  • [44] Real-world Safety Data of Rituximab among Mexican Patients with Neuromyelitis Optica AQP4-IgG serum positive from 2007 to 2024
    Coutinho Thomas, Domingo
    Gonzalez Perez, Karla
    Evangelista Osorio, Arath Amauri
    Martinez Lopez, Yazmin
    Rivas, Veronica
    Corona Vazquez, Teresita
    Flores Rivera, Jose de Jesus
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1118 - 1119
  • [45] Predictors of brand-switching among smokers in the United States and Canada: Findings from the ITC 4-Country Survey
    Cummings, KM
    Hyland, A
    Higbee, C
    Chaloupka, F
    Fong, GT
    NICOTINE & TOBACCO RESEARCH, 2005, 7 (04) : 699 - 699
  • [46] Long-term safety and effectiveness of eculizumab in patients with AQP4+neuromyelitis optica spectrum disorder: 3 years of data from Japanese post-marketing surveillance
    Nakahara, Jin
    Nakashima, Ichiro
    Yokote, Hiroaki
    Manabe, Yasuhiro
    Okamura, Kazumi
    Hasegawa, Kou
    Fujihara, Kazuo
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 144 - 144
  • [47] A Global, Long-Term, Prospective, Observational Registry of Patients With Anti-Aquaporin-4 Antibody-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated With Complement Component 5 Inhibitor Therapies (C5ITs) Eculizumab or Ravulizumab
    Fam, Sami
    Przybyl, Lindsey
    Azad, Tania
    Stankowski, Jeannette
    Moy, Kristin
    NEUROLOGY, 2024, 103 (07) : S55 - S55
  • [48] Satralizumab Treatment in Adult Patients With AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder Switching From Other Therapies: A Case Series
    Moghaddam, Shervin
    Steingo, Brian
    Vargas, Diana
    Patel, Julie
    Nealon, Nancy
    Willis, Mary
    Khaitov, Dmitry
    Ornelas, Jose
    Subei, Adnan
    Mao-Draayer, Yang
    Ferayorni, Lisa
    Laucirica, Xavier
    Abboud, Hesham
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [49] Satralizumab Treatment in Adult Patients With AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder Switching From Other Therapies: A Case Series
    Abboud, H.
    Steingo, B.
    Vargas, D.
    Patel, J.
    Nealon, N.
    Willis, M.
    Khaitov, D.
    Ornelas, J. Avila
    Subei, A.
    Ferayorni, L.
    Laucirica, X.
    Gholizadeh, S.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 174 - 174
  • [50] Demographics, comorbidities, and comedications in newly diagnosed patients with Alzheimer's disease and related dementias: Findings from United States Medicare claims data
    Schroeder, Krista M.
    Afonso, Ana Sofia
    Wang, Huabo
    Grace, Sarah
    Phipps, Adam
    Sims, John R.
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 102 (02) : 506 - 519
12345